RTI Surgical's C-Plus™ PEEK Interbody Fusion system is now indicated for use with allograft, including the company's proprietary map3® cellular allogeneic bone graft. This builds upon a previous indication for use solely with autograft.
Other 2016 regulatory announcements for RTI include:
- Expansion of 510(k) clearance for the Streamline OCT Occipito-Cervico-Thoracic System, including an indication for polyaxial screw placement in the cervical spine, and also clearance for a dual diameter transition rod
- Australia regulatory clearance for nanOss® Bioactive bone void filler
- CE Mark approval for nanOss Bioactive Loaded and nanOss Bioactive 3D in Europe
Sources: RTI Surgical, Inc.; ORTHOWORLD Inc.